Cardimed Drug Interactions

Beta-Blockers: In most patients, Nicardipine hydrochloride injection can safely be used concomitantly with beta-blocker. However, caution should be exercised when using Nicardipine hydrochloride injection in combination with beta-blocker in congestive heart failure patients.
Cimetidine: Cimetidine has been shown to increase Nicardipine plasma concentrations with Nicardipine hydrochloride capsule administration. Patients receiving the two drugs concomitantly should be carefully monitored. Data with other histamine-2 antagonists are not available.
Digoxin: Studies have shown that Nicardipine hydrochloride capsules usually do not alter Digoxin plasma concentrations. However, as a precaution, digoxin levels should be evaluated when concomitant therapy with Nicardipine hydrochloride is initiated.
Fentanyl Anesthesia: Hypotension has been reported during Fentanyl anaesthesia with concomitant use of a beta-blocker and a calcium channel blocker. Even though such interactions were not seen during clinical studies with Nicardipine hydrochloride injection (Nicardipine hydrochloride), an increased volume of circulating fluids might be required if such an interaction were to occur.
Cyclosporine: Concomitant administration of Nicardipine hydrochloride capsules and Cyclosporine results in elevated plasma cyclosporine levels. Plasma concentrations of Cyclosporine should therefore be closely monitored during Nicardipine hydrochloride injection administration, and the dose of Cyclosporine reduced accordingly.
In Vitro Hydrochloride: The plasma protein binding of Nicardipine was not altered when therapeutic concentrations of furosemide, propranolol, dipyridamole, warfarin, quinidine, or naproxen were added to human plasma in vitro.